Certain statements contained herein are "forward-looking" statements, including statements that the clinical study related to periodontal disease has the potential to lead to broad reimbursement of our PST test and a new insurance model for oral healthcare and that research findings related to osteoarthritis progression could enable the identification of early disease patients who may benefit from new drugs in development to modify the progression of the disease. Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, those risks and uncertainties described in the Company's annual report on Form 10-K for the year ended December 31, 2009 and other filings with the Securities and Exchange Commission. The Company disclaims any obligation or intention to update these forward-looking statements. INTERLEUKIN GENETICS, INC.FINANCIAL HIGHLIGHTSBalance Sheet Data : December 31, December 31,20102009Cash and cash equivalents$
906,248Total current assets$
3,069,463Total current liabilities$
8,834,091Total shareholders' defi
|SOURCE Interleukin Genetics, Inc.|
Copyright©2010 PR Newswire.
All rights reserved